NY-ALKYMI
Today, Alkymi announced that it has raised $5M in Seed funding to automatically free data from email and documents through a first-ever Data Inbox for enterprises . Canaan led the round with additional participation from prior investor Work-Bench and new investor SimCorp. Joydeep Bhattacharyya - General Partner at Canaan - will join Alkymi’s board.
Today, half of enterprise work-flow is held up by unstructured data log jammed in email inboxes and employees spend hours every day processing and synthesizing data. Alkymi’s machine learning-based platform frees that data from email and makes it instantly actionable in existing business processes such as finance, operations, human resources, CRM, sales, and IT.
“Over a 20-year career in enterprise software, I’ve learned that customers want software with transformative impact that is also easy to integrate into existing workflows,” said Harald Collet, founder and CEO of Alkymi. “Customers tell us that our Data Inbox and self-automated technology frees up their business analysts from data entry to actually do what their jobs should be - generating business insight.”
Alkymi has designed the platform to be intuitive for users - integrating easily into existing workflows without the creation of new apps or processes. As a result, Business Analysts using Alkymi report that they are able to generate insights twice as quickly, improving retention and satisfaction of their own customers.
“Alkymi Data Inbox has the potential to transform how the enterprise operates in the 21st century,” said Joydeep Bhattacharyya, General Partner at Canaan. “It is incredibly rare to see the kind of traction that Alkymi has with large marquee customers at the seed stage – a testament to both the market opportunity and the superb Alkymi team.”
Alkymi is also announcing a new machine learning partnership with global investment software provider SimCorp, an initiative designed to address increasing data challenges for institutional investors. The partnership brings insight and automation to SimCorp’s clients by integrating Alkymi’s technology within the market-leading SimCorp Dimension platform.
“Having worked alongside Alkymi for the past year and having done significant research on the space, it's clear that Alkymi is a one of a kind automated, elegant and ready-to-go solution,” said Jonathan Lehr, co-founder and General Partner at Work-Bench. “We introduced Alkymi to our extensive network of corporate executives and their overwhelmingly positive feedback gave us added confidence that Alkymi is solving a real and timely pain point in unlocking unstructured data from email."
Alkymi was co-founded by Harald Collet who saw this problem from the inside as an executive at Oracle and at Bloomberg L.P., where he launched Bloomberg Vault, a new SaaS product that he grew to more than 1,000 customers in 5 years. Co-founders Adam Kleczewski (Chief Data Scientist) and Steven She (CTO) collaborated at a prior startup, x.ai, building an intelligent personal assistant.
About Alkymi
Alkymi is delivering the first Data Inbox to the enterprise, freeing huge volumes of data from the email morass. Through world-class engineering, data science, and machine learning, Alkymi makes data instantly actionable. The company was founded in 2017 and is based in New York City. Learn more at alkymi.io.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005216/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom